| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Balázs Döme | Q42748261 |
| P2093 | author name string | József Tímár | |
| Sándor Paku | |||
| Mary J C Hendrix | |||
| József Tóvári | |||
| P2860 | cites work | VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche | Q24600542 |
| Differential regulation of EphA2 in normal and malignant cells | Q24684095 | ||
| Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis | Q24684263 | ||
| Blood supply of metastatic hepatic tumors: suggestions for improved delivery of chemotherapeutic agents | Q74688391 | ||
| Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia | Q74845840 | ||
| Low-dose metronomic chemotherapy: myth or truth? | Q80013357 | ||
| Development of the vasculature in "pushing-type" liver metastases of an experimental colorectal cancer | Q81437351 | ||
| Antiangiogenic effects of radiotherapy but not initial microvessel density predict survival in inoperable oropharyngeal squamous cell carcinoma | Q82747437 | ||
| Antiangiogenic therapy: a universal chemosensitization strategy for cancer? | Q83854395 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| The biology of VEGF and its receptors | Q27860704 | ||
| Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth | Q28203327 | ||
| Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer | Q28376841 | ||
| Angiogenesis in life, disease and medicine | Q29614539 | ||
| Regulation of angiogenesis by hypoxia: role of the HIF system | Q29619187 | ||
| Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels | Q29619679 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| Thalidomide in solid tumours: the resurrection of an old drug | Q33208578 | ||
| Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. | Q33221782 | ||
| First steps of tumor-related angiogenesis | Q33266252 | ||
| New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. | Q33739301 | ||
| Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry | Q33874221 | ||
| Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research | Q34174522 | ||
| Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy | Q34275617 | ||
| Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry | Q34979775 | ||
| Angiogenesis and vascular remodeling by intussusception: from form to function | Q35088146 | ||
| Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma | Q35141769 | ||
| Molecular plasticity of human melanoma cells | Q35146549 | ||
| Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery | Q35746429 | ||
| Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. | Q35764035 | ||
| The anti-angiogenic basis of metronomic chemotherapy | Q35788112 | ||
| Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. | Q35848435 | ||
| Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy | Q35848919 | ||
| Endothelial progenitor cells for postnatal vasculogenesis | Q35861865 | ||
| Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models | Q35867538 | ||
| Cellular abnormalities of blood vessels as targets in cancer | Q36015542 | ||
| Differentiation and definition of vascular-targeted therapies. | Q36035268 | ||
| Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions | Q36046661 | ||
| Disrupting tumour blood vessels | Q36146900 | ||
| Circulating endothelial progenitor cells. | Q36270419 | ||
| Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models | Q36294794 | ||
| Evidence for a role of platelet endothelial cell adhesion molecule-1 in endothelial cell mechanosignal transduction: is it a mechanoresponsive molecule? | Q36325631 | ||
| Integrins and angiogenesis: a sticky business | Q36330257 | ||
| Lessons from phase III clinical trials on anti-VEGF therapy for cancer | Q36366446 | ||
| Erythropoietin biology in cancer. | Q36374675 | ||
| Cancer-related anemia and recombinant human erythropoietin--an updated overview | Q36415312 | ||
| Current status of angiogenesis inhibitors combined with radiation therapy | Q36483330 | ||
| A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
| Current development status of small-molecule vascular disrupting agents | Q36511131 | ||
| Metronomic therapy from a pharmacologist's view | Q36516347 | ||
| Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. | Q36552808 | ||
| The hypoxic inducible stress response as a target for cancer drug discovery | Q36557316 | ||
| Morphological aspects of angiogenesis in experimental liver metastases. | Q36696756 | ||
| Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. | Q40353239 | ||
| Focal adhesion kinase promotes the aggressive melanoma phenotype. | Q40355320 | ||
| Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. | Q40479307 | ||
| Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway | Q40484626 | ||
| Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. | Q40587632 | ||
| Tumour versus patient: vascular and tumour survival versus prognosis | Q40716557 | ||
| Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal | Q40848490 | ||
| Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients | Q42491465 | ||
| Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry | Q43830684 | ||
| A novel concept of glomeruloid body formation in experimental cerebral metastases | Q44496375 | ||
| Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy | Q44730510 | ||
| Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis | Q44975603 | ||
| The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism | Q45248496 | ||
| Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer | Q46781781 | ||
| Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer | Q46983142 | ||
| Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. | Q47663109 | ||
| Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. | Q51345347 | ||
| Molecular determinants of human uveal melanoma invasion and metastasis. | Q52833056 | ||
| Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. | Q55476886 | ||
| Effects of Angiogenesis Inhibitors on Vascular Network Formation by Human Endothelial and Melanoma Cells | Q57373805 | ||
| Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers | Q59238447 | ||
| Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth | Q68994253 | ||
| Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models | Q73365474 | ||
| Tumor response to radiotherapy regulated by endothelial cell apoptosis | Q73401346 | ||
| Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance | Q74456778 | ||
| Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix | Q74606525 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1-15 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications | |
| P478 | volume | 170 |
Search more.